911 results about "Immunosuppression" patented technology

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention discloses a bispecific cytokine fusion protein, which comprises an amino acid sequence of a type I cytokine and an amino acid sequence of a type II cytokine, and the amino acid sequence of the type I cytokine and the amino acid sequence of the type II cytokine are directly connected through a connecting peptide or are connected in series or in parallel through a fusion partner and the connecting peptide. Amino acid sequences of type I and type II cytokines are connected in series or in parallel to form the bispecific cytokine fusion protein, and the fusion protein can synergistically activate precursor depleted CD8 + T cells and terminal depleted CD8 + T cells, improve immunosuppression of a solid tumor complex microenvironment and release the potential of tumor immunotherapy. The invention further discloses nucleic acid, a carrier, a cell, a medicine or a medicine composition related to the bispecific cytokine fusion protein. The invention also discloses application of the bispecific cytokine fusion protein in preparation of drugs for treating cancers.

The invention provides a nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as a preparation method and application of the nano photosensitizer. The nano photosensitizer is a nano material with the particle size of 80-120 nm, and the nano photosensitizer modified by the genetically engineered bacterium outer membrane vesicle comprises dipalmitic acid phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl lecithin (DOPC), cholesterol, a small molecule dye and CD47nb-OMV membrane protein. The chemical structure of the small molecule dye is shown as a formula I or a formula II. The nano photosensitizer OBDlp modified by outer membrane vesicles of genetically engineered bacteria serves as a novel nano photosensitizer, tumor targeting PTT is mediated through NIR II FL / PA imaging, tumor immunogenicity is improved, antigen presenting cells are activated, and infiltration and functionalization of CD8 + T cells are caused. And OBDlp and laser are combined to induce release of a large amount of DAMPs and trigger ICD to promote maturation of cDC1s. Meanwhile, a CD47 nano antibody carried by the nano photosensitizer induces polarization of M1 phenotype macrophages by blocking a CD47-SIRP alpha signal transduction axis, and an immunosuppression tumor microenvironment is reversed.

The invention belongs to the cross technical field of nanomedicine, tumor treatment and immunotherapy, and particularly provides tumor mitochondria-targeted copper death selective induction nanoparticles, which are prepared by the following preparation method: S1, specifically coupling TPY and MHI through condensation reaction to obtain MTPY; s2, MTPY and copper ions are subjected to complexation, and an MTPY-Cu complex is obtained; and S3, the MTPY-Cu complex and albumin are subjected to self-assembly, and the MTPY-Cu-coated Alb nanoparticles are formed. The dosage of copper is only 1 / 1000 of that of free Cu < 2 + >, and equivalent immune regulation and killing effects can be achieved; primary tumors and distant tumor focuses can be inhibited, and lung metastasis is reduced; immune memory can be induced, and relapse can be prevented; the traditional Chinese medicine composition is combined with cis-platinum to remarkably enhance the curative effect and reverse the induced immunosuppression; the invention has the advantages of high biological safety and no obvious liver and kidney toxicity or hemolytic reaction.

The invention relates to a colorectal cancer treatment effect prediction system based on artificial intelligence and multiple immunohistochemistry, which comprises: (i) an analysis selection module for analyzing tumor tissues and selecting target cells and / or target antigens; (ii) a preparation module for preparing a colorectal cancer immunosuppressive unit (CCIM) image from the selected target antigen by using a multiplex immunohistochemical technique; and (iii) an identification module that predicts a therapeutic effect of colorectal cancer based on the CCIM image.

The invention belongs to the technical field of biology, and particularly relates to a cryptosporidium parvum infection immunosuppression mouse model and a construction method thereof. Aiming at the problem that the development of cryptosporidiosis drugs and vaccines is seriously limited due to the fact that no model for successfully infecting mice with cryptosporidium parvum exists at present, the invention provides the construction method of the cryptosporidium parvum infection immunosuppression mouse model, which comprises the following steps: firstly, carrying out gavage treatment on the mice for 4-7 days by adopting cyclophosphamide; constructing to obtain an immunosuppressive mouse; feeding PBS (Phosphate Buffer Solution) containing cryptosporidium parvum oocysts through the mouth, and infecting for 7-21 days; and when oocysts are continuously detected from excrement of the mouse and the content of the oocysts is higher than the infection amount, constructing the cryptosporidium parvum infection immunosuppression mouse model. The cryptosporidium parvum infection immunosuppression mouse model is successfully constructed, can be used for subsequent drug and vaccine development tests for cryptosporidium parvum diseases, and has a good application prospect.

An anti-PD1 (programmed cell death 1) monoclonal antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof and use thereof. The heavy chain variable region of the monoclonal antibody comprises CDRs (complementary determining region) of amino acid sequences as shown in SEQ ID NO:9-11; and / or the light chain variable region of the monoclonal antibody comprises CDRs of amino acid sequences as shown in SEQ ID NO: 12-14. The monoclonal antibody can bind to PD1 specifically, relieve immunosuppression of PD1 on an organism specifically and activate T lymphocytes.

The invention belongs to the technical field of biomedical treatment, and discloses a preparation method of immunomodulatory recombinant macrophage vesicles, and the preparation method specifically comprises the following steps: step 1, clinical sequencing of gingival tumor tissues and pathogenic microbiota data analysis; hybridizing and fusing a macrophage membrane infected by the porphyromonas gingivalis and an exosome membrane; and 3, constructing a piezoelectric driven ROS (reactive oxygen species) to generate the immunoregulation vesicles. The invention provides an innovative nano vesicle technology, and the technology shows double advantages in tumor treatment: firstly, accurate targeting and efficient killing of key porphyromonas gingivalis in a tumor environment are realized by constructing recombinant macrophage vesicles, and meanwhile, the stability of normal flora is kept, and tumor deterioration is prevented; and secondly, the anti-tumor immune response is obviously activated by utilizing the immunoregulation capability of the bacteria-induced macrophages and exosome vesicles thereof, including converting immunosuppressed M2 type macrophages into anti-tumor M1 type macrophages, so that the growth of solid tumors is effectively inhibited.

The invention discloses a preparation method of a doxorubicin-loaded ginseng selenium polysaccharide nano-carrier with immunoregulation and liver cancer cell inhibition functions, and aims to solve the problems of toxic injury of tissues and organs and inhibition of an immune system caused by an antitumor drug doxorubicin. According to the invention, deoxycholic acid is grafted on the ginseng selenium polysaccharide, so that the ginseng selenium polysaccharide is hydrophobized and forms an amphiphilic polysaccharide polymer, and the limitations of large molecular weight, low bioavailability and the like of the ginseng selenium polysaccharide are overcome. The self-assembled ginseng selenium polysaccharide nanoparticles are used as carriers for delivering antitumor drugs, so that the self-assembled ginseng selenium polysaccharide nanoparticles have an immunoregulation effect and can effectively improve side effects such as immunosuppression caused by the antitumor drugs; and the carrier also has a pH sensitive response release characteristic, so that the targeting effect of the medicine in a tumor area is enhanced, and the innovative carrier has a good clinical application prospect.

The invention discloses a Trop2 targeting chimeric antigen receptor macrophage as well as a preparation method and application thereof. The macrophage contains a specific CAR (chimeric antigen receptor) targeting Trop2 and a blocking agent for blocking an immunosuppression signal; the amino acid sequence of the Trop2 specific CAR targeting the breast cancer is as shown in SEQ ID NO. 1; the nucleotide sequence of the mRNA of the specific CAR of the targeted Trop2 is as shown in SEQ ID NO. 2. According to the invention, LNP is adopted to co-deliver CAR mRNA and TLR agonists, and macrophages are edited in vivo to generate CAR-macrophages expressing Trop2 in situ, so that a tedious engineering cell in-vitro preparation process is omitted, and potential whole-body toxic and side effects caused by immune cell system reinfusion are avoided.

The invention relates to the technical field of biological medicine, in particular to the field of cell therapy, and particularly relates to application of STAR and immune cells comprising the STAR to treatment and / or prevention of tumors, an antigen binding region of the STAR comprises one or more than two of an antibody, a ligand or an antibody fusion body which binds to LILRB4, the antibody such as scFv or VHH, and the ligand and the antibody fusion body can be combined with the LILRB4. Wherein the LILRB4 is used as a tumor antigen and / or a receptor in an immunosuppressive active cell. According to the invention, the targeted killing effect of immune cells on tumors is enhanced by targeting tumor cells and / or reducing immune escape caused by immunosuppressive active cells.

The invention provides an application of a CXCR6 + PDCD1 + TOX + T cell in predicting the curative effect of hepatocellular carcinoma immunotherapy. In particular, the present invention provides a new depleted T cell subset, called TEX3 cells (CXCR6 + PDCD1 + TOX + T cells). In HBV + HCC, the TEX3 cells become an effective tumor killer. In addition, the TEX3 cell shows that the TEX3 cell obviously interacts with macrophages rich in CXCL9 and PD-L1 in HBV + HCC, a stronger immunosuppression tumor environment is shown, and the TEX3 cell obviously exists in a patient, so that the TEX3 cell shows an obviously better treatment effect.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

The invention discloses a double-target chimeric antigen receptor for co-expression of CD47 and IL-15, a CAR-T cell and application of the CAR-T cell, and belongs to the technical field of genetic engineering, the double-target chimeric antigen receptor comprises a single-chain antibody scFv-EGFRv III, a single-chain antibody scFv-VEGF, CD47 and IL-15; the nucleotide artificial sequence of the single-chain antibody scFv-EGFRv III is as shown in SEQ ID NO. 6; the nucleotide artificial sequence of the single-chain antibody scFv-VEGF is as shown in SEQ ID NO. 9. According to the application disclosed by the invention, by performing sequence optimization on targets EGFRvIII and VEGF, the anti-tumor effect of CAR-T cells in glioblastoma can be improved, and by integrating immune checkpoint molecules CD47 and interleukin-15, the immunosuppression function of a CD47-SIRP alpha signal channel can be locally exerted.

The invention relates to the field of biological medicines, in particular to a chimeric cytokine activated receptor for activating lymphocytes by using soluble immunosuppressive molecules and application of the chimeric cytokine activated receptor in tumor treatment. The chimeric cytokine activation receptor and a chimeric antigen receptor for recognizing tumor antigens are connected in parallel to form a co-expressed polycistron structure. Wherein the chimeric cytokine activation receptor comprises an scFv structural domain, a transmembrane structural domain and a cytokine chimeric activation structural domain which specifically recognize and bind soluble immunosuppressive molecules. The CAR-NK cell can specifically recognize soluble inhibitory factors in the tumor microenvironment and improve the in-vivo and in-vitro anti-tumor efficacy of the CAR-NK cell, and can be used for treating solid malignant tumors.

The invention relates to the technical field of genetic engineering and biological agents, in particular to a hybrid peptide with immunoregulation and anti-oxidation functions and a preparation method and application of the hybrid peptide. The polypeptide provided by the invention has immunoregulation and antioxidation functions at the same time, and in a normal or immunosuppression state, the polypeptide can significantly improve the immunologic function of a body and reduce the damage of immunosuppression to the body; the oxidation resistance of cells and organisms can be enhanced; meanwhile, the polypeptide has the advantages of low cytotoxicity, high safety, simplicity and convenience in preparation and low cost, can be used as an ideal immunomodulator and an antioxidant, is widely applied to the fields of medicines, foods, health care, feeds, nutrition and the like of human and animals, and has very good application potential and value.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The invention relates to a preparation method of a tumor microenvironment response type nano drug delivery system, which comprises the following steps: forming MnO2 nanoclusters through biomineralization induction under an alkaline condition, modifying HSA nanoparticles, then loading Ce6 through a carbodiimide method, and finally combining with a PD-L1 antibody by adopting a copper-free click chemistry method to obtain nanoparticles HMC and anti-PD-L1. The nanoparticle can be retained in a tumor tissue in a passive targeting manner through an EPR effect, and is decomposed into Mn < 2 + >, O2 and a small molecule drug through a high H2O2 and low pH microenvironment of the tumor tissue, so that the tumor permeability is greatly enhanced, the tumor immunogenicity is enhanced by combining sonodynamic therapy, the release of a tumor specific antigen and the aging of antigen presenting cells are promoted, and the tumor treatment effect is enhanced. The infiltration of tumor T cells is increased, and cold tumors are changed into hot tumors; the nanoparticles can generate O2 in situ at the same time, and the immunosuppressive ability and drug resistance caused by tumor hypoxia are overcome.

The invention discloses an engineered NK cell and a preparation method thereof. The antitumor activity of the NK cell is enhanced through synergistic modification of a fusion polypeptide and an anti-TIGIT monoclonal antibody. The amino acid sequence of the fusion polypeptide is shown as SEQ ID NO.1. The fusion polypeptide can specifically target tumor cells and activate the proliferation and killing functions of NK cells. And the anti-TIGIT monoclonal antibody further relieves the immunosuppression by blocking a TIGIT-CD155 signal channel. In-vitro experiments show that the killing rate of the combined modified NK cell on various solid tumors is obviously higher than that of the traditional CAR-NK cell. A PDX model shows that the engineered NK cells significantly inhibit tumor growth and enhance NK cell infiltration in a tumor microenvironment. The invention provides a new strategy with high efficiency and low toxicity for immunotherapy of solid tumors.

The invention discloses a pH-responsive deformable dual-targeting nano protein and a preparation method and application thereof, the method comprises the following steps: activating carboxylated mannose through an EDC / NHS system, reacting with an albumin solution, and dialyzing and purifying to obtain mannose modified albumin; and mixing the mannose modified albumin with an inhibitor IRG1-IN-1, and loading the IRG1-IN-1 through a hydrophobic effect to obtain the mannose albumin nanoparticles, ferritin serves as a carrier, oxaliplatin is loaded through a solvent replacement method, and ferritin nanoparticles are obtained; cHO-PEG2k-CHO is used as a coupling agent, and the mannose albumin nanoparticles and the ferritin nanoparticles are crosslinked through a Schiff base reaction, so that the large-size pH-responsive dual-targeting nano-protein is formed. The nano protein has the characteristic of double-targeting separability, so that specific treatment can be realized, immune cell metabolism is interfered while tumor cells are killed, metabolic immunosuppression is blocked, and anti-tumor immunotherapy is promoted.

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as V-domain immunoglobulin suppressor of T-cell activation (VISTA) inhibitors or as dual inhibitors of VISTA and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA and its ligands, PD-1, PD-L1, and / or PD-L2.

The invention discloses a function-enhanced mesenchymal stem cell preparation obtained by utilizing arthritis effusion and hypoxia pretreatment of mesenchymal stem cells as well as a preparation method and application of the function-enhanced mesenchymal stem cell preparation, and relates to the technical field of biological medicines. The preparation method of the function-enhanced mesenchymal stem cell preparation obtained by utilizing arthritis effusion and hypoxia pretreatment of mesenchymal stem cells comprises the following steps: S1, obtaining mesenchymal stem cells and performing hypoxia amplification passage; s2, pretreatment of arthritis effusion; S3, pre-stimulation of the arthritis effusion of the mesenchymal stem cells to obtain function-enhanced mesenchymal stem cells; s4, index detection and screening; s5, preparing a function-enhanced mesenchymal stem cell preparation; optimized low-oxygen pretreatment is adopted, so that the cell activity is improved; the mesenchymal stem cells subjected to joint pretreatment of arthritis effusion and hypoxia enhance expression and secretion of anti-inflammatory factors and immunomodulatory molecules in the cells; the pre-stimulated mesenchymal stem cells show a stronger immunosuppression function in vitro.

The invention relates to betulinic acid type saponin derivatives as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The structural general formula of the betulinic acid type saponin derivative is # imgabs0, R1 is selected from hydroxyl or-O-G, and G is monosaccharide; r2 is selected from dopamine, 5-aminovaleric acid, 4-aminobutyric acid or 3-aminopropionic acid and the like and salts thereof. The betulinic acid type saponin derivative does not show obvious cytotoxicity to THP-1 macrophages, and can obviously reduce the release of IL-6 and IL-1beta in the THP-1 macrophages induced by LPS (lipopolysaccharide). Compared with betulinic acid and positive control medicine mesalazine, the pharmaceutical composition has better anti-inflammatory activity, has the treatment effect of improving diarrhea and hemafecia of mice with colitis remarkably superior to those of betulinic acid and positive control medicine mesalazine, has the treatment effect of dermatitis superior to that of positive control medicine dexamethasone, and does not have obvious toxic or side effects such as weight loss and immunosuppression. Therefore, the betulinic acid type saponin derivative has good in-vivo and in-vitro safety and druggability.

The invention discloses a drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation as well as a preparation method and application thereof. By constructing the medicine-loaded mesenchymal stem cell preparation, the immunosuppression capacity of the mesenchymal stem cells is improved, the angiogenesis capacity of the mesenchymal stem cells is reduced, meanwhile, by releasing the glucocorticoid medicine at a low dosage, the side effect of single administration is avoided, M2 type macrophage polarization is induced, the inflammatory state of cartilage cells is improved, and the effect of treating the cartilage cells is achieved. The curative effect of the mesenchymal stem cells on osteoarthritis is improved in multiple aspects, and the mesenchymal stem cells are proved in animal bodies. The drug-guided anti-inflammatory enhanced mesenchymal stem cell preparation provides a new thought for the treatment of osteoarthritis.

The invention belongs to the technical field of biomedicine, and discloses a nano-particle for enhancing radioimmunotherapy effect through cascade reaction and application of the nano-particle, a preparation method of the nano-particle comprises the following steps: S1, synthesis of ZnO2; the preparation method comprises the following steps: dissolving ZnCl2 and PVP in absolute ethyl alcohol, adding ammonia water and H2O2, after the reaction is completed, collecting precipitates, washing, and dispersing the precipitates in absolute ethyl alcohol to prepare ZnO2; and S2, synthesis of ZnO2 (at) Cu: resuspending ZnO2 in water, sequentially adding ammonia water, a PAA solution, IPA, dopamine hydrochloride and a CuCl2 solution, stirring in a nitrogen atmosphere, centrifuging, washing with ethanol, and drying in vacuum to obtain the ZnO2 (at) Cu nano-particles, namely the nano-particles. According to the nanoparticles, the radiotherapy effect is enhanced through cascade reaction, copper death is induced, immune response is activated, effective treatment on tumors is achieved, and the problems of radiotherapy resistance and immunosuppressive tumor microenvironment are solved.

The invention discloses a nonapeptide with an immunomodulatory effect as well as preparation and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the nonapeptide QT9 is Gln-Pro-Gln-Pro-Pro-Phe-Ser-His-Thr, and the amino acid sequence of the nonapeptide QT9 is shown in the specification. The peptide fragment can be obtained through artificial synthesis or directional enzymolysis of wheat protein. Functional verification shows that the nonapeptide has the effects of promoting immune cell proliferation, improving the immune factor level, improving the immune organ index and improving the immune function of intestinal mucosa. Moreover, the nonapeptide QPQPPFSHT is a natural peptide fragment and is high in biological safety, so that the nonapeptide QPQPPFSHT can be applied to preparation of food or medicines for preventing and improving the undesirable phenomenon of immunosuppression. A new solution is provided for improving the immune function, the requirements of the public for immune health care are met, and good market prospects and application potential are achieved.

The invention provides a fermented beverage capable of relieving fatigue and a preparation method of the fermented beverage, and relates to the technical field of functional beverages, and the IPC classification number belongs to A23L2. The fermented beverage is prepared from a radix astragali fermentation extract, a radix platycodonis extract, L-arginine, taurine, inositol, caffeine, nicotinamide, vitamin B6, L-lysine hydrochloride, pyrroloquinoline quinone and auxiliary materials. The astragalus mongholicus fermentation extract can improve the ATP generation efficiency, reduce lactic acid accumulation after exercise, relieve damage of oxidative stress to muscle and nerve cells and reduce immunosuppression caused by fatigue; the platycodon grandiflorum extract has the effects of refreshing mind and restoring consciousness, improving cognitive function decline caused by central fatigue, enhancing capillary permeability and promoting removal of metabolic wastes. The radix astragali fermentation extract and the radix platycodonis extract are compounded to achieve a synergistic effect, so that the composition has an excellent anti-fatigue effect. Under the combined action of all the components, fatigue is relieved, energy is rapidly supplemented, and physical strength is recovered.

The invention discloses a preparation method and application of an ovotransferrin oligomer with an immunomodulatory effect, and a function enhanced nano oligomer is constructed through an enzymatic crosslinking and dynamic hot pressing synergistic treatment technology. The preparation method comprises the following specific steps: preparing an ovotransferrin solution, adjusting the pH value to 1.5-2.0, carrying out high-pressure homogenization and double-frequency ultrasonic treatment after pre-denaturation, adding TG enzyme to catalyze, crosslink and induce controllable aggregation, and finally freeze-drying to obtain oligomer powder, the oligomer is of a nano-scale spherical structure, the particle size is 50-200nm, the solubility is good, and the immunoregulation function is remarkably enhanced. Comprising the steps of promoting dendritic cells to secrete immune factors, prolonging the survival time of nematodes under bacterial infection and improving the immune function of immunosuppressive mice. The method disclosed by the invention is simple in process, green and environment-friendly, suitable for the fields of functional health-care products, pharmaceutical preparations, formula foods with special medical purposes and the like, and wide in application prospect.